Neu-601

Neu-601 is a preclinical drug candidate being developed by Neurim Pharmaceuticals for the treatment of Parkinson's disease. Neurim Pharmaceuticals is a drug discovery and development company that focuses on the central nervous system, particularly through the modulation of melatonin receptors and circadian rhythms. While the specific molecular target of Neu-601 has not been publicly disclosed, the company's research platform typically involves small molecule ligands designed to provide neuroprotective effects or address neurodegenerative pathologies. Neu-601 is part of an early-stage pipeline aimed at addressing the underlying mechanisms or symptomatic manifestations of Parkinson's disease.